Increased Ige Level In Blood

Track level

2392172 5unit
EUR 25.06

Ige Antibody Laboratories manufactures the increased ige level in blood reagents distributed by Genprice. The Increased Ige Level In Blood reagent is RUO (Research Use Only) to test human serum or cell culture lab samples. To purchase these products, for the MSDS, Data Sheet, protocol, storage conditions/temperature or for the concentration, please contact ige antibody. Other Increased products are available in stock. Specificity: Increased Category: Ige Group: Level In

True Blue Chloride

100mg
EUR 11200
Description: 71431-30-6

JBS True Blue

300 µl
EUR 16
Description: JBS True Blue

Blood, Pigeon in Alsevers

50mL
EUR 1510

Blood, Pigeon in Alsevers

5x50mL
EUR 6640

IgE Antibody

1 mg Ask for price

IgE Antibody

1 ml Ask for price

IgE Antibody

1 mg Ask for price

Level In information

PMS2L5, CT (PMS2P5, PMS2L5, PMS4, PMS7, Postmeiotic segregation increased 2-like protein 5, Postmeiotic segregation increased protein 4, Postmeiotic segregation increased protein 7, Putative postmeiotic segregation increased 2 pseudogene 5) (MaxLight 650)

MBS6335232-5x01mL 5x0.1mL
EUR 4250

PMS2L5, CT (PMS2P5, PMS2L5, PMS4, PMS7, Postmeiotic segregation increased 2-like protein 5, Postmeiotic segregation increased protein 4, Postmeiotic segregation increased protein 7, Putative postmeiotic segregation increased 2 pseudogene 5) (MaxLight 750)

MBS6335233-01mL 0.1mL
EUR 980

PMS2L5, CT (PMS2P5, PMS2L5, PMS4, PMS7, Postmeiotic segregation increased 2-like protein 5, Postmeiotic segregation increased protein 4, Postmeiotic segregation increased protein 7, Putative postmeiotic segregation increased 2 pseudogene 5) (MaxLight 750)

MBS6335233-5x01mL 5x0.1mL
EUR 4250

PMS2 (Postmeiotic Segregation Increased 2)

MO47015 100 ul
EUR 418.8

PMS2 (Postmeiotic Segregation Increased 2)

MBS556114-01mL 0.1mL
EUR 455

PMS2 (Postmeiotic Segregation Increased 2)

MBS556114-5x01mL 5x0.1mL
EUR 1895

PMS2 Antibody / Post Meiotic Segregation Increased 2

V5202-100UG 100ug
EUR 363.3
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.

PMS2 Antibody / Post Meiotic Segregation Increased 2

V5202-20UG 20ug
EUR 160.3
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.

PMS2 Antibody / Post Meiotic Segregation Increased 2

V5202SAF-100UG 100ug
EUR 363.3
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.

PMS2 Antibody / Post Meiotic Segregation Increased 2

V5203-100UG 100ug
EUR 363.3
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.

PMS2 Antibody / Post Meiotic Segregation Increased 2

V5203-20UG 20ug
EUR 160.3
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.

PMS2 Antibody / Post Meiotic Segregation Increased 2

V5203SAF-100UG 100ug
EUR 363.3
Description: PMS2 is involved in DNA mismatch repair. It forms a heterodimer with MLH1 and this complex interacts with other complexes bound to mismatched bases. Defects in PMS2 are the cause of hereditary non-polyposis colorectal cancer type 4 (HNPCC4). Mutations in more than one gene locus can be involved alone or in combination in the production of the HNPCC phenotype (also called Lynch syndrome). Most families with clinically recognized HNPCC have mutations in either MLH1 or MSH2 genes. HNPCC is an autosomal, dominantly inherited disease associated with marked increase in cancer susceptibility. It is characterized by a familial predisposition to early onset colorectal carcinoma (CRC) and extra-colonic cancers of the gastrointestinal, urological and female reproductive tracts. HNPCC is reported to be the most common form of inherited colorectal cancer in the Western world, and accounts for 15% of all colon cancers. Defects in PMS2 are a cause of mismatch repair cancer syndrome (MMRCS); also known as Turcot syndrome or brain tumor-polyposis syndrome 1 (BTPS1). MMRCS is an autosomal dominant disorder characterized by malignant tumors of the brain associated with multiple colorectal adenomas. Skin features include sebaceous cysts, hyperpigmented and cafe au lait spots.

Postmeiotic Segregation Increased 2 (PMS2) (PT2116) Antibody

N1752-100uL 100uL
EUR 122.5
Description: Human Postmeiotic Segregation Increased 2 (PMS2) (PT2116) Mouse Monoclonal Antibody

Postmeiotic Segregation Increased 2 (PMS2) (PT2116) Antibody

N1752-50uL 50uL
EUR 66.5
Description: Human Postmeiotic Segregation Increased 2 (PMS2) (PT2116) Mouse Monoclonal Antibody

Postmeiotic Segregation Increased 2-Like Protein 5 (PMS2L5) Antibody

abx030611-400ul 400 ul
EUR 627.6

Postmeiotic Segregation Increased 2-Like Protein 5 (PMS2L5) Antibody

abx030611-80l 80 µl
EUR 343.2

Postmeiotic Segregation Increased 2-Like Protein 5 (PMS2L5) Antibody

abx030611-400l 400 µl
EUR 518.75